 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...3536373839404142434445...235236» |
- Avastin (bevacizumab) / Roche, aplitabart (IGM-8444) / IGM Biosciences
A randomized Phase 1b study of IGM-8444 in combination with FOLFIRI + bevacizumab compared to FOLFIRI + bevacizumab alone in second line metastatic colorectal cancer. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_523;
- fosifloxuridine nafalbenamide (NUC-3373) / NuCana, Keytruda (pembrolizumab) / Merck (MSD)
Phase Ib/II open label, multi-arm, parallel cohort dose finding and expansion study of NUC-3373 in combination with pembrolizumab in patients with advanced solid tumors or docetaxel in patients with lung cancer (NuTide:303). (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_521;
- fosifloxuridine nafalbenamide (NUC-3373) / NuCana, Avastin (bevacizumab) / Roche
Phase II study of NUC-3373, leucovorin, irinotecan (NUFIRI) + bevacizumab vs FOLFIRI + bevacizumab for the second-line treatment of patients with advanced/metastatic colorectal cancer (NuTide:323). (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_374;
- fosifloxuridine nafalbenamide (NUC-3373) / NuCana, Avastin (bevacizumab) / Roche
NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302). (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_373;
- irinotecan / Generic mfg.
A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111 / DEP irinotecan) in patients with advanced solid tumours. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_364;
- aplitabart (IGM-8444) / IGM Biosciences
Pharmacokinetics and pharmacodynamics of IGM-8444, a first-in-class engineered pentameric DR5-targeting agonist IgM monoclonal antibody, in patients with R/R and newly diagnosed cancers. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_290;
- Pancreas organoid immune co-culture system identifies immunomodulators in pancreas adenocarcinoma. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_229;
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. (Pubmed Central) - Sep 15, 2023
The present study confirms that neoadjuvant FOLFIRINOX is associated with excellent survival and demonstrates that active smoking reduces its benefit. The nomogram can assist in daily clinical practice and emphasises the importance of smoking cessation in patients with PDAC, especially prior to NAT with FOLFIRINOX.
- | Imfinzi (durvalumab) / AstraZeneca, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Journal, Metastases: Systemic treatment of patients with locally advanced or metastatic cholangiocarcinoma - an Austrian expert consensus statement. (Pubmed Central) - Sep 15, 2023
Its combination with the immune checkpoint inhibitor durvalumab resulted in an efficiency improvement in the phase III setting...The evidence base for nanoliposomal irinotecan (Nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) is contradictory...These targeted agents are generally preferable to second-line chemotherapy. Broad molecular testing should be performed, preferably from tumor tissue, at the initiation of first-line therapy to timely identify potential molecular targets.
- || ompenaclid (RGX-202) / Inspirna, EMD Serono
Enrollment open, Combination therapy, Metastases: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 15, 2023
P2, N=50, Recruiting, Sponsor: Inspirna, Inc.
Broad molecular testing should be performed, preferably from tumor tissue, at the initiation of first-line therapy to timely identify potential molecular targets. Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche
Enrollment closed: SOLARIS: Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 14, 2023
P3, N=455, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | BI 905711 / Boehringer Ingelheim
Trial completion date, Combination therapy, Metastases: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - Sep 13, 2023
P1a/1b, N=13, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Trial completion date: Sep 2024 --> Mar 2024
- | irinotecan / Generic mfg.
Trial completion date, Trial primary completion date: XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study) (clinicaltrials.gov) - Sep 13, 2023
P=N/A, N=24, Recruiting, Sponsor: Guangzhou University of Traditional Chinese Medicine
Trial completion date: Sep 2024 --> Mar 2024 Trial completion date: May 2023 --> Oct 2024 | Trial primary completion date: May 2023 --> Aug 2024
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly
Trial completion date: AVETRIC: AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Sep 13, 2023
P2, N=58, Active, not recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
Trial completion date: May 2023 --> Oct 2024 | Trial primary completion date: May 2023 --> Aug 2024 Trial completion date: Dec 2023 --> Jul 2024
- | Journal, Metastases: Age-related trends in the incidence of (Pubmed Central) - Sep 13, 2023
Trial completion date: Dec 2023 --> Jul 2024 A retrospective, observational study describing temporal trends in mCRC incidence and FOLFOXIRI treatment by age group using a nationwide database of commercially and Medicare Advantage-insured patients from 2010
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Clinical data, Journal, Real-world evidence, Real-world, Metastases: Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study. (Pubmed Central) - Sep 13, 2023
Nal-IRI plus 5FU/LV had modest survival benefits and an acceptable safety profile in patients with prior conventional IRI. A longer interval between conventional IRI and nal-IRI was associated with increased survival outcomes.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Protective effect of miR-18a in resected liver metastases of colorectal cancer and FOLFOX treatment. (Pubmed Central) - Sep 12, 2023
A longer interval between conventional IRI and nal-IRI was associated with increased survival outcomes. High expression of miR-18a in colorectal liver metastases might have a protective effect after resection of metastases and FOLFOX treatment regarding PFS.
- ||| 5-fluorouracil / Generic mfg.
P2/3 data, Journal, Metastases: GRECCAR 14 - a multicentric, randomized, phase II-III study evaluating the tailored management of locally advanced rectal carcinoma after a favourable response to induction chemotherapy: study protocol. (Pubmed Central) - Sep 12, 2023
High expression of miR-18a in colorectal liver metastases might have a protective effect after resection of metastases and FOLFOX treatment regarding PFS. If GRECCAR 14 demonstrates the ability to tailor TNT for LARC, this could lead to changes in clinical practice.
- | methotrexate IV / Generic mfg., leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Journal: High-Dose Methotrexate: Nursing Considerations for Administration and Supportive Care. (Pubmed Central) - Sep 11, 2023
Using existing and novel tools, nurses can closely monitor patients and provide supportive care to mitigate HDMTX toxicity. Early identification of delayed MTX elimination and subsequent treatment with glucarpidase, if appropriate, has been associated with shorter length of hospital stay and decreased incidence of grade 4 toxicities and mortality.
- | BI 905711 / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - Sep 11, 2023
P1a/1b, N=13, Active, not recruiting, Sponsor: Boehringer Ingelheim
Early identification of delayed MTX elimination and subsequent treatment with glucarpidase, if appropriate, has been associated with shorter length of hospital stay and decreased incidence of grade 4 toxicities and mortality. Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Mar 2024
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment change, Metastases: Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer (clinicaltrials.gov) - Sep 11, 2023
P2, N=12, Active, not recruiting, Sponsor: University of Rochester
Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Mar 2024 N=40 --> 12
- ||| BMS-986322 / BMS
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants (clinicaltrials.gov) - Sep 11, 2023
P1, N=76, Recruiting, Sponsor: Bristol-Myers Squibb
N=40 --> 12 Not yet recruiting --> Recruiting | N=44 --> 76 | Trial completion date: Jan 2023 --> Nov 2023 | Trial primary completion date: Jan 2023 --> Nov 2023
- || Review, Journal, Metastases: Management of Metastatic Pancreatic Cancer-Comparison of Global Guidelines over the Last 5 Years. (Pubmed Central) - Sep 9, 2023
The newest guidelines suggest that molecular profiling of the tumor should be the first step in determining the course of treatment. The use of modern molecular therapies in patients with specific gene mutations should extend the survival of patients with this disease.
- | 5-fluorouracil / Generic mfg.
Journal: Induction Fluorouracil-Based Chemotherapy and PET-Adapted Consolidation Chemoradiation with Esophagectomy for High-Risk Gastroesophageal Adenocarcinoma. (Pubmed Central) - Sep 9, 2023
Induction FOLFOX/FLOT chemotherapy with evaluation of sensitivity via metabolic response and tailored chemoradiation seems to lead to high pCR and ypN0 rates in high-risk patients with adenocarcinoma of the esophagus and GE junction. This approach in clinical practice seems to recapitulate encouraging results in clinical trials.
- ||| 5-fluorouracil / Generic mfg.
Journal, Adverse events: Muscle and Adipose Wasting despite Disease Control: Unaddressed Side Effects of Palliative Chemotherapy for Pancreatic Cancer. (Pubmed Central) - Sep 9, 2023
The greatest muscle and adipose losses were independently associated with reduced survival (muscle: HR 1.72, p = 0.007; adipose: HR 1.73, p = 0.012; tertile 1 versus tertile 3). Muscle and adipose losses are adverse effects of chemotherapy and may require regimen-specific management strategies.
- | 5-fluorouracil / Generic mfg.
Retrospective data, Journal, Metastases: The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting-A Nation-Wide Retrospective Analysis (RACER). (Pubmed Central) - Sep 9, 2023
We have conducted a retrospective multicentre study to collect data on real-world population characteristics, practice patterns, and outcomes in patients with metastatic colorectal cancer treated in a first-line setting with either cetuximab or panitumumab in combination with either FOLFOX or FOLFIRI chemotherapy...OS data was incomplete. The presented analysis confirms the negative impact of tumour sidedness on the efficacy of an upfront anti-EGFR-chemotherapy combination and provides valuable data on real-world population characteristics.
- | Lonquex (lipegfilgrastim biosimilar) / Teva
Journal: Analyzing Flow Cytometry or Targeted Gene Expression Data Influences Clinical Discoveries-Profiling Blood Samples of Pancreatic Ductal Adenocarcinoma Patients. (Pubmed Central) - Sep 9, 2023
This highlights that different techniques influence clinical discoveries. Therefore, it is important to carefully select the measurement technique used to study the effect of a treatment.
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (clinicaltrials.gov) - Sep 8, 2023
P3, N=1007, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Therefore, it is important to carefully select the measurement technique used to study the effect of a treatment. Trial primary completion date: Jun 2024 --> Feb 2023
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., docetaxel / Generic mfg.
New P2/3 trial, Metastases: OCTASUR: Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer (clinicaltrials.gov) - Sep 8, 2023
P2/3, N=758, Recruiting, Sponsor: Ukrainian Society of Clinical Oncology
- || Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer
P2 data, Journal, Metastases: First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. (Pubmed Central) - Sep 7, 2023
P2
Regorafenib can be safely combined with nivolumab and chemotherapy and showed promising activity in HER2-negative metastatic oesophagogastric cancer. A randomised, phase 3 clinical trial is planned.
- | Avastin (bevacizumab) / Roche
Journal: Combination of Targeted Therapies for Colorectal Cancer Treatment. (Pubmed Central) - Sep 7, 2023
Here, we show that the combination of two targeted therapies, including bevacizumab (Bev), and a ?-glucuronidase-responsive albumin-binding prodrug of monomethyl auristatin E (MMAE), is efficient for the treatment of colorectal cancer implanted in mice...The increased anticancer efficacy is due to either a synergistic or an additive effect between Bev and MMAE selectively released from the glucuronide prodrug in the tumor microenvironment. Since numerous drug delivery systems such as antibody-drug conjugates employ MMAE as a cytotoxic payload, this finding may be of great interest for improving their therapeutic index by combining them with Bev, particularly for the therapy of colorectal cancer.
- | Journal, Epigenetic controller: DNA methylation-associated allelic inactivation regulates Keratin 19 gene expression during pancreatic development and carcinogenesis. (Pubmed Central) - Sep 7, 2023
Since numerous drug delivery systems such as antibody-drug conjugates employ MMAE as a cytotoxic payload, this finding may be of great interest for improving their therapeutic index by combining them with Bev, particularly for the therapy of colorectal cancer. KRT19 protein was additionally detected in plasma of PDAC patients, with higher concentrations correlating with shorter progression-free survival in gemcitabine/nabPaclitaxel-treated and opposing trends in FOLFIRINOX-treated patients..
- || Lumakras (sotorasib) / Amgen
Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Sep 7, 2023
P1b/2, N=1143, Recruiting, Sponsor: Amgen
KRT19 protein was additionally detected in plasma of PDAC patients, with higher concentrations correlating with shorter progression-free survival in gemcitabine/nabPaclitaxel-treated and opposing trends in FOLFIRINOX-treated patients.. Trial primary completion date: Jan 2025 --> May 2026
- || bemarituzumab (AMG 552) / Amgen
Trial completion date, Trial primary completion date: FORTITUDE-102: Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (clinicaltrials.gov) - Sep 7, 2023
P1b, N=528, Recruiting, Sponsor: Amgen
Trial primary completion date: Jan 2025 --> May 2026 Trial completion date: Jan 2027 --> Sep 2026 | Trial primary completion date: Jan 2027 --> Sep 2026
- | NN1213 / Novo Nordisk
Biomarker, Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Surgery: TRIGGER: Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial (clinicaltrials.gov) - Sep 7, 2023
P3, N=441, Recruiting, Sponsor: Imperial College London
Trial completion date: Jan 2027 --> Sep 2026 | Trial primary completion date: Jan 2027 --> Sep 2026 Phase classification: P2/3 --> P3 | N=90 --> 441 | Trial completion date: Dec 2026 --> Dec 2034 | Trial primary completion date: Dec 2021 --> Dec 2027
- |||| nisevokitug (NIS793) / Novartis
Enrollment open, Enrollment change: daNIS-3: Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (clinicaltrials.gov) - Sep 7, 2023
P2, N=268, Recruiting, Sponsor: Novartis Pharmaceuticals
Phase classification: P2/3 --> P3 | N=90 --> 441 | Trial completion date: Dec 2026 --> Dec 2034 | Trial primary completion date: Dec 2021 --> Dec 2027 Active, not recruiting --> Recruiting | N=205 --> 268
- ||| 5-fluorouracil / Generic mfg.
Retrospective data, Journal, Adverse events, Combination therapy, Metastases: Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis. (Pubmed Central) - Sep 7, 2023
In the appropriate clinical scenario, the use of aflibercept in its approved indications remains justified. However, the results of this study should be interpreted with caution, as some of the evidence comes from single-arm clinical trials.
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Trial completion date: AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 6, 2023
P3, N=218, Active, not recruiting, Sponsor: Children's Oncology Group
However, the results of this study should be interpreted with caution, as some of the evidence comes from single-arm clinical trials. Trial completion date: Jul 2023 --> Jun 2024
- || Enrollment closed, Trial completion date: Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma (clinicaltrials.gov) - Sep 6, 2023
P1, N=20, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Jul 2023 --> Jun 2024 Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Oct 2026
- | Vectibix (panitumumab) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date: PANIRINOX: Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Sep 5, 2023
P2, N=219, Active, not recruiting, Sponsor: UNICANCER
Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Oct 2026 Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Primary Hepatic Mixed Neuroendocrine Nonneuroendocrine Neoplasm, Amphicrine Variant: A Rare Case (In-Person) - Sep 4, 2023 - Abstract #CAP2023CAP_184;
There are no standardized therapeutic regimens for MiNENs, because of the heterogeneous nature of the tumor and its rarity. Improved diagnostic modalities and a keen eye are helpful in diagnosing these lesions.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Evaluation of Pathological Response Rate and Complications of FOLFOX versus FLOT Regimen in Perioperative Chemotherapy for Resectable Gastric Cancer: A Prospective Study. (Pubmed Central) - Sep 2, 2023
The frequency of neurological complications and hair loss was significantly higher in patients treated with FLOT regimen. Thus, perioperative FLOT regimen may be recommended for treating GC patients.
- | Trial primary completion date, Metastases: ChanghaiH-PP05: Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer (clinicaltrials.gov) - Sep 1, 2023
P1/2, N=60, Recruiting, Sponsor: Changhai Hospital
Thus, perioperative FLOT regimen may be recommended for treating GC patients. Trial primary completion date: Nov 2022 --> Nov 2023
- Tasigna (nilotinib) / Novartis, Inhibikase
Secondary Chronic Myeloid Leukemia Following Successful Treatment of Metastatic Colon Cancer: A Case Report (LEVEL 3, GENERAL ASSEMBLY) - Aug 31, 2023 - Abstract #SOHO2023SOHO_520;
Fluorouracil and oxaliplatin can cause translocation in bone marrow stem cells. So, it is suggested that a complete blood count be checked after treatment in the follow-up of solid tumors.
- | Vectibix (panitumumab) / Amgen, Takeda
Journal: Early-stage sigmoid colon cancer resection followed by liver metastasis recurrence 1 (Pubmed Central) - Aug 31, 2023
So, it is suggested that a complete blood count be checked after treatment in the follow-up of solid tumors. Even early-stage CRCs that have no pathological indications for additional resection have risks of metastases and recurrences, and we may need to consider that the criteria for additional resection should not be limited to pathological findings alone.
- | Trial completion date: PROTECT: PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer (clinicaltrials.gov) - Aug 31, 2023
P2, N=106, Active, not recruiting, Sponsor: Centre Oscar Lambret
Even early-stage CRCs that have no pathological indications for additional resection have risks of metastases and recurrences, and we may need to consider that the criteria for additional resection should not be limited to pathological findings alone. Trial completion date: Jun 2023 --> Nov 2023
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: High vs. low-dose leucovorin in regimens with fluorouracil in colorectal cancer therapy. (Pubmed Central) - Aug 30, 2023
In 17 cases, the departments for the preparation of cytostatics in the Czech Republic had to accept restrictions on administering the full dose of leucovorin. These restrictions consisted of reducing the dose of the injectable form of leucovorin, changing the chemotherapy regimen, administering the oral form of calcium folinate, forcing a therapeutic break, or a combination of these approaches.
- | 5-fluorouracil / Generic mfg.
Journal, Compliance: Association between Pre-Treatment Biological Indicators and Compliance to Neoadjuvant/Perioperative Chemotherapy in Operable Gastric Cancer. (Pubmed Central) - Aug 30, 2023
Fat loss and sarcopenia do not appear to be related to compliance. More information is needed to reduce the causes of interruption.
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment change, Trial withdrawal, Combination therapy, Metastases: CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 30, 2023
P1, N=0, Withdrawn, Sponsor: Cornerstone Pharmaceuticals
More information is needed to reduce the causes of interruption. N=12 --> 0 | Not yet recruiting --> Withdrawn
- |||| oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Enrollment status: FROST: Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer (clinicaltrials.gov) - Aug 30, 2023
P2/3, N=308, Enrolling by invitation, Sponsor: Chungnam National University Hospital
N=12 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Enrolling by invitation